Keyword search (4,163 papers available)

"SARS-CoV-2" Keyword-tagged Publications:

Title Authors PubMed ID
1 Energy Measures as Biomarkers of SARS-CoV-2 Variants and Receptors Ghannoum Al Chawaf K; Lahmiri S; 41596038
JMSB
2 Emerging hazardous chemicals and biological pollutants in Canadian aquatic systems and remediation approaches: A comprehensive status report Adeola AO; Paramo L; Fuoco G; Naccache R; 39278485
CHEMBIOCHEM
3 Insomnia symptoms among older adults during the first year of the COVID-19 pandemic: A longitudinal study Gong K; Garneau J; Grenier S; Vasiliadis HM; Dang-Vu TT; Dialahy IZ; Gouin JP; 37380593
HKAP
4 Two Chemical Engineers Look at the COVID-19 Pandemic De Visscher A; Pinheiro PatrĂ­cio PC; 35942051
ENCS
5 Evaluating SARS-CoV-2 airborne quanta transmission and exposure risk in a mechanically ventilated multizone office building Yan S; Wang LL; Birnkrant MJ; Zhai J; Miller SL; 35602249
ENCS
6 Predicted coronavirus Nsp5 protease cleavage sites in the human proteome Scott BM; Lacasse V; Blom DG; Tonner PD; Blom NS; 35379171
ENCS
7 COVID-19-Related Concerns and Symptoms of Anxiety: Does Concern Play a Role in Predicting Severity and Risk? Benzouak T; Gunpat S; Briner EL; Thake J; Kisely S; Rao S; 34987892
PSYCHOLOGY
8 Removal of SARS-CoV-2 using UV+Filter in built environment: simulation/evaluation by utilizing validated numerical method Feng Z; Cao SJ; Haghighat F; 34367884
ENCS
9 Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19 Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH; 34209188
CHEMBIOCHEM
10 Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2 Nguyen K; Chakraborty S; Mansbach RA; Korber B; Gnanakaran S; 34067878
PHYSICS
11 Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ; 34021862
CHEMBIOCHEM
12 Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection Safiabadi Tali SH; LeBlanc JJ; Sadiq Z; Oyewunmi OD; Camargo C; Nikpour B; Armanfard N; Sagan SM; Jahanshahi-Anbuhi S; 33980687
IMAGING
13 Indoor airborne disinfection with electrostatic disinfector (ESD): Numerical simulations of ESD performance and reduction of computing time Feng Z; Cao SJ; Wang J; Kumar P; Haghighat F; 33994653
ENCS
14 Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ; 33968364
CERMM
15 Identifying and addressing psychosocial determinants of adherence to physical distancing guidance during the COVID-19 pandemic - project protocol. Durand H, Bacon SL, Byrne M, Kenny E, Lavoie KL, McGuire BE, Mc Sharry J, Meade O, Mooney R, Noone C, O'Connor LL, O'Flaherty K, Molloy GJ 33490860
HKAP
16 Designing a hybrid reinforcement learning based algorithm with application in prediction of the COVID-19 pandemic in Quebec. Khalilpourazari S, Hashemi Doulabi H 33424076
ENCS
17 The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses. De Visscher A 32836820
ENCS

 

Title:The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses.
Authors:De Visscher A
Link:https://www.ncbi.nlm.nih.gov/pubmed/32836820
DOI:10.1007/s11071-020-05861-7
Publication:Nonlinear dynamics
Keywords:Case mortality rateDoubling timeHerd immunityR0SARS-CoV-2Social distancing
PMID:32836820 Category:Nonlinear Dyn Date Added:2020-08-25
Dept Affiliation: ENCS
1 Department of Chemical and Materials Engineering, Gina Cody School of Engineering and Computer Science, Concordia University, Montreal, QC Canada.

Description:

The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses.

Nonlinear Dyn. 2020 Aug 10; :1-17

Authors: De Visscher A

Abstract

An epidemiological model for COVID-19 was developed and implemented in MATLAB/GNU Octave for use by public health practitioners, policy makers, and the general public. The model distinguishes four stages in the disease: infected, sick, seriously sick, and better. The model was preliminarily parameterized based on observations of the spread of the disease. The model assumes a case mortality rate of 1.5%. Preliminary simulations with the model indicate that concepts such as "herd immunity" and containment ("flattening the curve") are highly misleading in the context of this virus. Public policies based on these concepts are inadequate to protect the population. Only reducing the R 0 of the virus below 1 is an effective strategy for maintaining the death burden of COVID-19 within the normal range of seasonal flu. The model is illustrated with the cases of Italy, France, and Iran and is able to describe the number of deaths as a function of time in all these cases although future projections tend to slightly overestimate the number of deaths when the analysis is made early on. The model can also be used to describe reopenings of the economy after a lockdown. The case mortality rate is still prone to large uncertainty, but modeling combined with an investigation of blood donations in The Netherlands imposes a lower limit of 1%.

PMID: 32836820 [PubMed - as supplied by publisher]





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University